OPIOIDS

1
OPIOIDS
0

• LINDA WUNDER,CRNA MSN
• NURSE ANESTHESIOLOGY
• FLORIDA INTERNATIONAL UNIVERSITY

2
OPIOIDS
0

• First, morphine in 1803 with active component
  opium
• Narcotic is greek for stupor and is referred to
  morphine-like analgesics with potential to
  produce physical dependence.

3
OPIODS
0

• Opioids act at stereospecific opioid receptors at
  presynaptic and postsynaptic sites in the central
  nervous system brain(periaqueductal gray,
  amygdala, corpus striam, and hypothalmus) and
  spinal cord(substanstantia geltinosa) and in the
  peripheral tissues.
• Endogenous ligands for the opioid receptors are
  collectively known as endorphins.
• The term endorphine comes from endo, meaning
  inside, and m-orphine, indicating opioid agonist.
  

4
OPIOIDS
0

• The endorphines are peptides that are released
  upon a painful stimuli
• They bind to opioid receptors to decrease the
  individuals perception of pain
• Endorphines include enkephlins, endorphines and
  dynorphins
• The opioid agonist mimic the endogenous
  endorphines and bind to the opioid receptors
  hence inhibiting pain transmission

5
OPIOIDS
0

• Ionized state is necessary for strong bonding at
  the anionic receptor site
• Only the levorotatory forms of the opioid exhibit
  agonist activity
• The affinity of most opioid agonists for
  receptors correlates well with their analgesic
  potency

6
OPIOIDS

• Opioids receptor activation decreases
  neurotransmission
• Mostly decreasing presynaptic release of
  acetylcholiene,dopamine,norepinephrine ,substance
  P(postsynaptic can occur)
• Substance P is an excitatory neurotransmitter
  presumed to be released by terminals of pain
  fibrs that synapse in the substansia gelatinosa
  of the spinal cord

7
OPIOIDS

• Opioid receptors are classified as mu, delta,
  kappa
• An ideal opioid agonist would have have high
  specificity for receptors, producing desirable
  responses (analgesia) and little or no
  specificity for receptors associated with side
  effects ( hypoventilation, nausea, physical
  dependence)

8
(No Transcript)
9
(No Transcript)
10
OPIOIDS
11
OPIOIDS

• EFFECTS
• Cv not a negative inotrope
• Respiratory- decrease respiratory rate and
  increase tidal volume.
• Decrease the co2 response in the medulla
• Chest wall rigidity-rapid administration of
  opioids increases airway pressure
• Spasm of biliary smooth muscle-sphincter of Oddi
• GI-constipation, N/V(stimulation of the
  chemotrigger zone floor of fouth ventricle)
• Placenta-opioid cross and produce fetal
  respiratory depression
• Miosis-excitatory action of edingerwestphal
  nucleus of the occularmottor nerve
• Awareness-not a hypnotic
• Decreases MAC requirements for inhalational
  anesthetics
• Tolerance occurs 2-3 weeks, dependence 25 days

12
OPIOIDS

• Onset 15-30min,1/2 time 1.7-3.3 hr
• 75-85 metab to morphine-3-glucuronide inactive
• 5-10 metab to morphine 6-glucuronide, produces
  analgesia and resp depression via mu activation
• Metab conjugationwtih glucuronic acid
• Releases histamine

• MORPHINE

13
OPIOIDS

• MEPERIDINE
• 1/10 as potent as morphine
• Duration 2-4 hours
• Mu and kappa receptor agonist
• Structurally similar to atropine, derived from
  phenylepiperidine
• 90 metabolized to normeperidine,1/2 as active as
  a analgesic
• Normeperidine toxicity causes myoclonus and
  seizures
• No miosis, causes mydriasis, large doses causes
  decrease in myocardial contractility
• Do not administer if patient is taking moa
  inhibitors,cns excitation hypotension
• Treatment for postop shivering

14
OPIOIDS

• FENTANYL

15
OPIOIDS

• FENTANYL-phenylpiperidine derivative
• 75-125 more potent than morphine
• Rapid onset, highly lipid soluble
• First pass-75 initial dose to lungs
• Duration of action is by redistribution rather
  than elimination, slowly released and elimination
  by the liver-N-demethylation and excreted by the
  urine

16
OPIOIDS

• FENTANYL
• Elimination half time is longer than morphine
  because Vd is larger and is more lipid soluble
• Stable hemodynamicno cardiac depressant effects,
  absence of histamine release, suppression of
  stress response during surgery

17
OPIOIDS

• 12 times more potent than fentanyl
• 60 first pass pulmonary uptake
• Smaller Vd than fentanyl
• Metabolized N dealkylation ,O demethylation

• SUFENTANIL

18
OPIOIDS

• ALFENTAto fentanyl but 1/5-1/10 as potent with
  1/3 duration
• Rapid onset 1.4 minslow PK
• 90 nonionized, Vd 4-6 times smaller than
  fentanyl, lower lipid solubility
• Bound to alph1 acid glycoprotein
• Metabolized piperidine N-dealkylation to
  noralfentanil and amide N-dealkylation to
  N-phenylpropionamide
• Interindividual variability inhibit metabolism
  especially alteration in P-450 for those taking
  erythromycin

19
OPIOIDS

• AGONIST/ANTAGONIST
• NALBUPHINE-NUBAIN
• Chemically related to oxymorphine and naloxone-as
  potent as morphine and ¼ as an antagonist
• Metabolized in liver with half time of 3 to 6
  hours
• 10-20 mg IV
• Reverses postop ventilatory depression effects of
  fentanyl maintaining the analgesia

20
OPIOIDS

• Opioid induced respiratory depression
• Metabolized conjugation-glucuronic acid to form
  naloxone 3-glucuronide
• Half time 60-90 minutes
• 1-4uq/kg IV
• Side effects tachycardia,hypertention,pulmonary
  edema,cardiac dysrhythmias,vfib
• Crosses placenta

• NALOXONE

21
Opioids
22
OPIOIDS

• NEURAXIAL
• Epidural or subarachnoid placement of opioids are
  based on mu receptors in the substancia
  gelatinosa of the spinal cord
• Epidural placement of opioids reflect diffusion
  of the drug across the dura to gain access to the
  mu opioid receptors on the spinal cord as well as
  systemic absorption to produce effects similar to
  those that would follow IV administration

23
OPIOIDS

• Side effects
• Pruritus
• N/V
• Urinary retention
• Depression of ventilation
• Sedation
• Central nervous system excitation
• Neonatal morbidity
• Viral reactivation
• Ocular dysfunction
• Sexual dysfunction
• GI dysfunction
• Thermoregulatory dysfunction
• Water retention

24
OPIOIDS

• Factors that increase risk of respiratory
  depression
• High opioid dose
• Low lipid solubility
• Concomitant administration of parental opiods or
  other sedatives
• Lack of opioid tolerance
• Advance age

25
KETOROLAC

• NSAIDs possess analgesic, antiinflamatory,
  antipyretic,and platelet inhibitory effects
• NSAIDs inhibition of cyclooxygenase activity and
  the resulting decrease in peripheral synthesis of
  prostaglandins

26
KETOROLAC

• NSAID potent analgesic, moderate antiinflammatory
• 30mg IM,produces analgesia that is equivalent to
  10 mg of morphine
• Has no ventilatory depression or biliary spasm
• Metabolized by glucuronic acid conjugation
• Clearance is decreased in elderly and dosed less
  in younger patients

27
KETOROLAC

• SIDE EFFECTS
• Bleeding
• Life threatening bronchospasm may follow if
  administered to patients with
• Nasal polyposis, asthma, and aspirin sensitivity